GH Research (GHRS) Shares Outstanding (2020 - 2026)
GH Research (GHRS) posted quarterly Shares Outstanding (Entity) of $24.4 million for Q4 2025, up 17.33% year-over-year from $20.8 million in Q4 2024, and down 1.59% quarter-over-quarter from $24.8 million in Q3 2025.
GH Research (GHRS) Shares Outstanding (2020 - 2026) Analysis & Trends
GH Research's Shares Outstanding (Entity) history runs 6 years deep, the most recent figure standing at $24.4 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 17.33% year-over-year to $24.4 million; the TTM figure through Dec 2025 stood at $24.4 million (up 17.33% YoY), while the FY2025 annual figure was $24.4 million, up 17.33% from the prior year.
- Shares Outstanding (Entity) for Q4 2025 stood at $24.4 million, down from $24.8 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $24.8 million in Q3 2025, with the low at $17.5 million in Q4 2021.
- The 5-year median for Shares Outstanding (Entity) is $20.8 million (2023), against an average of $21.5 million.
- The sharpest annual moves came in 2021 and 2023: Shares Outstanding (Entity) soared 54.03% in 2021, then changed 0.0% in 2023.
- GH Research's Shares Outstanding (Entity) stood at $17.5 million in 2021, then increased by 19.09% to $20.8 million in 2022, then climbed by 0.0% to $20.8 million in 2023, then advanced by 0.01% to $20.8 million in 2024, then grew by 17.33% to $24.4 million in 2025.
- Business Quant data shows GHRS's Shares Outstanding (Entity) at $24.4 million in Q4 2025, $24.8 million in Q3 2025, and $24.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | 66.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66.53 Mn |
| Dec 31, 2025 | 61.04 Mn |
| Sep 30, 2025 | 62.03 Mn |
| Jun 30, 2025 | 62.03 Mn |
| Mar 31, 2025 | 58.03 Mn |
| Dec 31, 2024 | 52.03 Mn |
| Sep 30, 2024 | 52.03 Mn |
| Jun 30, 2024 | 52.03 Mn |
| Mar 31, 2024 | 52.03 Mn |
| Dec 31, 2023 | 52.02 Mn |
| Sep 30, 2023 | 52.02 Mn |
| Jun 30, 2023 | 52.02 Mn |
| Mar 31, 2023 | 52.02 Mn |
| Dec 31, 2022 | 52.02 Mn |
| Sep 30, 2022 | 52.02 Mn |
| Jun 30, 2022 | 52.02 Mn |
| Mar 31, 2022 | 43.68 Mn |
| Dec 31, 2021 | 43.68 Mn |
| Sep 30, 2021 | 28.36 Mn |
| Jun 30, 2021 | 28.36 Mn |